Analyst Consensus ?
ConsensusHold14 ratings
Bullish857.1%
Neutral535.7%
Bearish17.2%
Amcor plc · AMCR · FY2024 Q4 · Calendar Q3 2024
Amcor enters FY25 with volume recovery, cost focus and execution risks
The supplied analysis supports a cautiously constructive operating thesis: volume recovery, productivity and higher-value growth initiatives provide support, but the evidence is not one-sided because destocking, inflation, restructuring and capital-allocation timing remain material constraints.
Reported After market closeNYSEConsumer Cyclical
$20.27B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$0.21
Consensus $0.20
EPS surprise
+5.0%
Reported versus consensus
Reported revenue
$3.54B
Consensus $3.62B
Revenue surprise
-2.3%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-3.7%
Event window
SPY move
+0.2%
Same window
Abnormal move
-3.9%
Stock minus SPY
Volume
1.8×
Versus trailing sessions
Subsequent drift
+6.4%
Up to 20 sessions
AMCRSPY benchmark
Ask FN2 about AMCR FY2024 Q4
Transcript, numbers and history already loaded
Why did AMCR fall 3.7% after beating EPS estimates in FY2024 Q4?What changed in AMCR's guidance and outlook in FY2024 Q4?Give me the bull and bear case for AMCR after FY2024 Q4 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter, management shifted from reporting improving volumes and raised guidance to outlining a maintained FY25 outlook. The plan now emphasizes higher capex for organic growth, completion of restructuring, selective M&A and a conditional return to share repurchases.
Guidance delta
FY25 EPS guidance was maintained at $0.72-$0.76, with management planning higher capex and continued cost, growth and M&A initiatives.
Key takeaways
- FY24 ended with volume growth, margin expansion and an EPS beat.
- Management described recovery across most geographies and categories, while healthcare destocking and North American beverage remained weaker areas.
- The FY25 plan combines higher capex, remaining restructuring savings, priority-category growth and selective M&A.
- The central debate is whether volume recovery and productivity can offset inflation, mix pressure and restructuring costs.
Management priorities
- Complete the restructuring program and capture remaining savings.
- Increase capex for organic growth and capacity flexibility.
- Pursue M&A in higher-value categories while advancing sustainability initiatives.
- Maintain dividend growth and resume share repurchases when cash flow permits.
Follow AMCR with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$43.85Current
$43Low
$52.78Average
$82.5High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 17, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| JP Morgan | Neutral | Overweight | Downgrade | Aug 17, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Aug 14, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 14, 2026 |
| Jefferies | Hold | Buy | Downgrade | Jul 22, 2026 |
| BMO Capital | Market Perform | Outperform | Downgrade | Jul 17, 2026 |
| B of A Securities | Buy | Buy | Maintain | Jul 14, 2026 |
| Truist Securities | Buy | Buy | Maintain | May 7, 2026 |
| Deutsche Bank | Buy | Hold | Upgrade | Apr 1, 2026 |
| Baird | Outperform | Neutral | Upgrade | Jan 7, 2026 |
| UBS | Buy | Neutral | Upgrade | Jun 26, 2025 |
| Macquarie | Outperform | Neutral | Upgrade | Nov 27, 2024 |
| Goldman Sachs | Sell | Sell | Maintain | May 3, 2023 |
| CLSA | Buy | Buy | Maintain | Jul 19, 2022 |
| Seaport Global | Neutral | Neutral | Maintain | Oct 14, 2020 |
Named analyst price targets
Upside is calculated against the persisted current price $43.85. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Truist Financial | Michael Roxland | $51 | $46.2 | +16.3% | Aug 18, 2026 |
| UBS | Nathan Reilly | $56 | $47.11 | +27.7% | Aug 11, 2026 |
| Jefferies | Ramoun Lazar | $44.92 | $43.44 | +2.4% | Jul 21, 2026 |
| BMO Capital | Analyst unavailable | $47 | $44.84 | +7.2% | Jul 16, 2026 |
| Wells Fargo | Analyst unavailable | $43 | $42.78 | -1.9% | Jul 15, 2026 |
| Wells Fargo | Analyst unavailable | $41 | $36.69 | -6.5% | May 20, 2026 |
| Truist Financial | Michael Roxland | $50 | $40.74 | +14.0% | Apr 15, 2026 |
| Robert W. Baird | Analyst unavailable | $54 | $44.92 | +23.1% | Feb 4, 2026 |
| Morgan Stanley | Joseph Michael | $46 | $44.2 | +4.9% | Jan 28, 2026 |
| Robert W. Baird | Ghansham Panjabi | $50 | $42.85 | +14.0% | Jan 7, 2026 |
| Truist Financial | Michael Roxland | $60 | $42.3 | +36.8% | Jan 6, 2026 |
| Morgan Stanley | Joseph Michael | $57.5 | $42.3 | +31.1% | Nov 12, 2025 |
| Wells Fargo | Analyst unavailable | $45 | $40.5 | +2.6% | Oct 15, 2025 |
| Stifel Nicolaus | Analyst unavailable | $51 | $39.72 | +16.3% | Oct 10, 2025 |
| Goldman Sachs | Analyst unavailable | $82.5 | $41.15 | +88.1% | Sep 10, 2025 |
| Truist Financial | Michael Roxland | $55 | $48.3 | +25.4% | Jul 11, 2025 |
| Wells Fargo | Gabe Hajde | $54 | $56.7 | +23.1% | Oct 15, 2024 |
| Stifel Nicolaus | Lars Kjellberg | $54 | $48.15 | +23.1% | Jul 9, 2024 |
| Wells Fargo | Gabe Hajde | $49 | $49.05 | +11.7% | Jun 28, 2024 |
Track every rating change on AMCR the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationAmcor plc stands as a prominent global provider of packaging solutions, focusing on the creation, production, and distribution of its diverse product portfolio across Europe, North America, Latin America, Africa, and the Asia Pacific regions. The company's operations are divided into two main segments: Flexibles and Rigid Packaging. The Flexibles division specializes in offering advanced flexible and film packaging solutions, catering to a wide array of industries including food and beverages, medical and pharmaceutical sectors, fresh produce, snack foods, and personal care items.…
Historical context
All AMCR earningsLatest beats and misses
Who reports nextBeat on EPS
Get the AMCR recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-10-17T05:10:49.140638+00:00
- Polygon adjusted daily market bars · 2026-10-17T09:30:41.921087+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-17T09:30:41.918056+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-17. For educational purposes only; not investment advice.